Alasdair is a leader in KPMGs Precision Medicine practice. He has over 20 years' experience in strategy consulting specializing in inorganic growth, RD and commercial strategy and portfolio optimization for biopharmaceutical, genomic, diagnostic and health system clients, as well as private investors. Alasdair has also worked with numerous prerevenue biotechnology companies to help them shape their equity story in preparation for capital raise. As a trained cancer biologist Alasdair helps clients solve complex business problems that require deep scientific and technical knowledge, and he has worked across multiple therapeutic areas, including CNS, hematology, immunology, infectious disease, metabolic diseases, oncology, respiratory, womens health, as well as rare and ultrarare diseases.
Precision Medicine: AI's Transformative Impact
Join us as we explore AI's transformative influence on Precision Medicine. From patient risk assessments to tailored treatments, we'll highlight generative AI's role and address emerging challenges like data privacy and ethics. Concluding, we'll guide through potential solutions, emphasizing the pivotal role of federated learning and other innovative processes.
AI and Data Sciences Showcase:
KPMG’s Precision Medicine practice is part of KPMG Healthcare and Life Sciences, supporting the development and execution of strategies across the HCLS continuum. Our practice is a leader across therapeutic areas and global markets, fueled by experience across the value chain.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.